Gemcitabine/Cisplatin±Sorafenib for the First-Line Treatment of Chemonaive Chinese Patients with Advanced, Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Subgroup Analysis of the Phase III NExUS Trial

被引：0
|
作者：
Liao, Meilin [1 ]
Zhang, Li [2 ]
Sun, Yan [3 ]
Yu, Shiying [3 ]
Pan, Hongming [4 ]
Zhou, Caicun
Jiang, Anastasia
Montegriffo, Elaine
Ong, Teng Jin
Gatzemeier, Ulrich [5 ]
机构：
[1] Shanghai Chest Hosp, Clin Med Ctr Lung Tumor, Dept Pulm Oncol, Shanghai, Peoples R China
[2] Sun Yat Sen Univ, Dept Oncol, Ctr Canc, Guangzhou, Guangdong, Peoples R China
[3] Tongji Hosp, Dept Oncol, Shanghai, Peoples R China
[4] Sir Run Run Shaw Hosp, Dept Oncol, Hangzhou, Zhejiang, Peoples R China
[5] Hosp Grosshansdorf, Dept Thorac Oncol, Grosshansdorf, Germany
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S374 / S374
页数：1
相关论文
共 50 条
  • [31] Economics of first-line treatment with tislelizumab in patients with nonsquamous non-small cell lung cancer
    Wang, Lin
    Liu, Ting
    Lin, Xihan
    Zhang, Yu
    Shi, Luwen
    You, Ruxu
    Liu, Jinyu
    IMMUNOTHERAPY, 2024, 16 (20-22) : 1217 - 1226
  • [32] Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Butts, C. A.
    Bodkin, D.
    Middleman, E. L.
    Englund, C. W.
    Ellison, D.
    Alam, Y. Z.
    Pautret, V.
    Weber, M.
    Kreisman, H.
    Shepherd, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] First-line cisplatin plus pemetrexed therapy for selected patients with advanced nonsquamous non-small cell lung cancer.
    Nakashima, Kazuhisa
    Murakami, Haruyasu
    Imai, Hisao
    Ono, Akira
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Endo, Masahiro
    Takahashi, Toshiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] 65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC).
    Schuette, Wolfgang
    Nagel, Sylke
    Schneider, Claus-Peter
    Engel-Riedel, Walburga
    Schumann, Christian
    Kohlhaeufl, Martin
    Serke, Monika
    Hoeffken, Gert
    Kortsik, Cornelius
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Phase II Trial of Thalidomide, Irinotecan and Gemcitabine in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer
    Jazieh, A. R.
    Komrokji, R.
    Gupta, A.
    Patil, S.
    Flora, D.
    Knapp, M.
    Issa, M.
    Karim, N. Abdel
    CANCER INVESTIGATION, 2009, 27 (09) : 932 - 936
  • [36] BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)
    Reck, Martin
    von Pawel, Joachim
    Zatloukal, Petr
    Ramlau, Rodryg
    Gorbounova, Vera
    Hirsh, Vera
    Leighl, Natasha
    Mezger, Joerg
    Archer, Venice
    Manegold, Christian
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S360 - S361
  • [37] Docetaxel/gemcitabine vs. cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC):: Results of a randomised phase II trial
    Binder, D
    Schweisfurth, H
    Grah, C
    Schäper, C
    Temmesfeld-Wollbrück, B
    Siebert, G
    Suttorp, N
    Beinert, T
    LUNG CANCER, 2005, 49 : S237 - S237
  • [38] Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer
    Sujith Kalmadi
    Giles McNeill
    Mellar Davis
    David Peereboom
    David Adelstein
    Tarek Mekhail
    Medical Oncology, 2006, 23 : 507 - 513
  • [39] Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer
    Kalmadi, Sujith
    McNeill, Giles
    Davis, Mellar
    Peereboom, David
    Adelstein, David
    Mekhail, Tarek
    MEDICAL ONCOLOGY, 2006, 23 (04) : 507 - 513
  • [40] Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
    Wu, Yi-Long
    Xu, Chong-Rui
    Hu, Cheng-Ping
    Feng, Jifeng
    Lu, Shun
    Huang, Yunchao
    Li, Wei
    Hou, Mei
    Shi, Jian Hua
    Maerten, Angela
    Fan, Jean
    Peil, Barbara
    Zhou, Caicun
    ONCOTARGETS AND THERAPY, 2018, 11 : 8575 - 8587
12345